Takeda Pharmaceutical Company Limited announced executive and directorate changes to be proposed in its AGM to be held on June 2017. Christophe Weber, Masato Iwasaki, James Kehoe, Andrew Plump, Yoshiaki Fujimori, Emiko Higashi, Michel Orsinger, Masahiro Sakane, and Toshiyuki Shiga to be appointed as candidates for Non-Audit and Supervisory Committee Directors. Audit and Supervisory Committee Directors to be appointed are Yasuhiko Yamanaka, Shiro Kuniya, Koji Hatsukawa and Jean-Luc Butel within their 2-year tenure, and are not subjects for reelection this year. Yasuchika Hasegawa, Shinji Honda, and Fumio Sudo to be appointed as Directors. Yasuchika Hasegawa will be appointed as Corporate Counselor upon the company request after retiring from Chairman of the Board. There will be no successor to Chairman Hasegawa on this occasion, Masahiro Sakane, who has been an External Director of Takeda since 2014, has kindly accepted to chair the board meeting after the General Meeting of Shareholders in June.